Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Julphar
Johnson and Johnson
Fuji
Dow
Merck
Teva
Chubb
Baxter

Generated: August 17, 2017

DrugPatentWatch Database Preview

RAPIVAB Drug Profile

« Back to Dashboard

Which patents cover Rapivab, and what generic Rapivab alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-four patent family members in twenty-seven countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.

Summary for Tradename: RAPIVAB

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list42
Clinical Trials: see list2
Patent Applications: see list39
Drug Prices:see details
DailyMed Link:RAPIVAB at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: RAPIVAB

Country Document Number Estimated Expiration
China1282316► Subscribe
Brazil9813480► Subscribe
Japan2008163035► Subscribe
European Patent Office1986626► Subscribe
Poland196674► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Medtronic
Cipla
Covington
Novartis
Cerilliant
Johnson and Johnson
AstraZeneca
Daiichi Sankyo
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot